Celldex (CLDX) Receives a Rating Update from a Top Analyst
at www.tipranks.com (Sat, 3-Oct 10:35 AM)
Celldex Highlights Phase 3 Barzolvolimab Data With Complete Response Near 54% at 24 Weeks in CSU
Market Chameleon (Tue, 22-Sep 11:36 AM)
Celldex reports Phase 3 barzolvolimab CSU wins as complete response rates approach 54% by Week 24
Market Chameleon (Tue, 22-Sep 7:28 AM)
